u/janek_ferrari

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

say how long you were on and at what dose before taper

the people who came off and restarted without shame

Yeah, regain is not a failure.

cite the discontinuation data rather than guessing regain rates

Adding to this: regain is doing more work than the comment implies.

Retitled to remove editorialising.

Yes, exactly this, and it is the bit that took me 87 weeks to accept.

retatrutide is not approved anywhere for human use, posts must not read as instructions

u-100 syringe, not u-40, or your math is off by factor of 3

body-composition claims need a method

Mechanistically the bit that matters is triple agonist. It explains most of the early profile and a decent chunk of the outcome.

The confident tone is doing a lot of work that the evidence is not.

Sceptical. If this were true we would see it reflected in the data and we do not.

Do you have baseline to compare to?

the 5mg arm is different from 5mg, results do not transfer

Yeah, 96.8% area is not the problem, the missing impurity breakdown is the problem.

sarcopenia is the unsolved question

Disagree. What you are describing is consistent with retatrutide, not with what you concluded.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

This is correct. Triple agonism is genuinely different.

cite the discontinuation data rather than guessing regain rates